Lista de obras - Angel M Cuesta - Dominio Público Uruguay

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

scientific article published in Nature Communications

Antibody engineering: facing new challenges in cancer therapy.

artículo científico publicado en 2005

Basement membrane-rich organoids with functional human blood vessels are permissive niches for human breast cancer metastasis

artículo científico publicado en 2013

CLN5 in heterozygosis may protect against the development of tumors in a VHL patient

artículo científico publicado en 2020

Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events.

artículo científico publicado en 2006

Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I

scientific article published on 01 April 2006

EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance

scientific article published on 29 July 2016

Improved stability of multivalent antibodies containing the human collagen XV trimerization domain.

artículo científico publicado en 2012

In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences

artículo científico publicado en 2009

Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains

artículo científico publicado en 2016

Long-term in vivo imaging of human angiogenesis: critical role of bone marrow-derived mesenchymal stem cells for the generation of durable blood vessels

scientific article published on 15 December 2007

Multivalent antibodies: when design surpasses evolution.

scientific article published on 04 May 2010

PHD3 controls lung cancer metastasis and resistance to EGFR inhibitors through TGFα.

artículo científico publicado en 2018

Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies